Literature DB >> 34729633

Angiographic findings in cases with a history of severe retinopathy of prematurity treated with anti-VEGFs: Follow-up to age 6 years.

Hande Celiker1, Ozlem Sahin2.   

Abstract

PURPOSE: To report the effects of anti-vascular endothelial growth factor (VEGF) treatment in vascular development for cases of acute retinopathy of prematurity (ROP) using fluorescent angiography (FA) and to present the results of our observational approach to retinal sequelae.
METHODS: A total of 31 eyes in 19 patients with a history of treatment with anti-VEGF agents for classic type 1 ROP and aggressive posterior ROP who underwent FA between March 2014 to February 2020 were reviewed. Angiograms of retinal developmental features of patients aged 4 months to 6 years were examined.
RESULTS: The patients mean gestational age were 26.06 ± 1.90 weeks and the mean birth weight were 837.68 ± 236.79 g. All cases showed various abnormalities at the vascular and avascular retina, and the posterior pole. All but one case showed a peripheral avascular area on FA evaluation during the follow-up period. We did not apply prophylactic laser treatment to these avascular retina. On the final examination, except one case, we did not observe any late reactivation in any patients.
CONCLUSION: FA is an important tool for assessing vascular maturation in infants. Every leakage should not be assumed to be evidence of late activation, as some leaks may be related to vascular immaturity. Retinal vascularization may not be completed in all patients, however this does not mean that all these patients need prophylactic laser application. Our observational approach may be more daring than the reports frequently encountered in the literature, but it should be noted that unnecessary laser treatment will also eliminate all the advantages of anti-VEGF treatment.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Anti-VEGFs; Fluorescein angiography; Late recurrence; RetCam; Retinopathy of prematurity

Mesh:

Substances:

Year:  2021        PMID: 34729633     DOI: 10.1007/s10792-021-02119-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  29 in total

1.  Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children.

Authors:  Michael P Blair; Michael J Shapiro; M Elizabeth Hartnett
Journal:  J AAPOS       Date:  2012-06       Impact factor: 1.220

Review 2.  Retinopathy of prematurity care: screening to vitrectomy.

Authors:  Lisa J Faia; Michael T Trese
Journal:  Int Ophthalmol Clin       Date:  2011

Review 3.  New insights in diagnosis and treatment for Retinopathy of Prematurity.

Authors:  Linda A Cernichiaro-Espinosa; Francisco J Olguin-Manriquez; Andree Henaine-Berra; Gerardo Garcia-Aguirre; Hugo Quiroz-Mercado; Maria A Martinez-Castellanos
Journal:  Int Ophthalmol       Date:  2016-01-14       Impact factor: 2.031

4.  Changes in causes of low vision between 1988 and 2009 in a Dutch population of children.

Authors:  Nienke Boonstra; Hans Limburg; Nel Tijmes; Maria van Genderen; José Schuil; Ruth van Nispen
Journal:  Acta Ophthalmol       Date:  2011-08-04       Impact factor: 3.761

5.  Retinopathy of prematurity in middle-income countries.

Authors:  C Gilbert; J Rahi; M Eckstein; J O'Sullivan; A Foster
Journal:  Lancet       Date:  1997-07-05       Impact factor: 79.321

6.  Persistent Avascular Retina in Infants With a History of Type 2 Retinopathy of Prematurity: To Treat or Not to Treat?

Authors:  Rasha Al-Taie; Samantha K Simkin; Erica Douçet; Shuan Dai
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2019-07-01       Impact factor: 1.402

7.  Atlas of fluorescein angiographic findings in eyes undergoing laser for retinopathy of prematurity.

Authors:  Domenico Lepore; Fernando Molle; Monica M Pagliara; Antonio Baldascino; Carmine Angora; Maria Sammartino; Graham E Quinn
Journal:  Ophthalmology       Date:  2010-08-14       Impact factor: 12.079

8.  Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Lorenzo Orazi; Antonio Baldascino; Marco H Ji; Maria Sammartino; Fabio Sbaraglia; Daniela Ricci; Eugenio Mercuri
Journal:  Ophthalmology       Date:  2017-09-01       Impact factor: 12.079

9.  Reactivation of retinopathy of prematurity after ranibizumab treatment.

Authors:  Ryan K Wong; Sasha Hubschman; Irena Tsui
Journal:  Retina       Date:  2015-04       Impact factor: 4.256

10.  Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Antonio Baldascino; Lorenzo Orazi; Maria Sammartino; Velia Purcaro; Carmen Giannantonio; Patrizia Papacci; Costantino Romagnoli
Journal:  Ophthalmology       Date:  2014-07-04       Impact factor: 12.079

View more
  1 in total

1.  Morphology and Vessel Density of the Macula in Preterm Children Using Optical Coherence Tomography Angiography.

Authors:  Agnieszka Czeszyk; Wojciech Hautz; Maciej Jaworski; Dorota Bulsiewicz; Justyna Czech-Kowalska
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.